Compare Datadog Inc (DDOG) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs DexCom, Inc. — how do they compare? Datadog Inc trades at $273.66 (market cap $98.31B), while DexCom, Inc. trades at $84.38 (market cap $31.86B). The key difference: Datadog Inc is far larger — about 3.1× DexCom, Inc.'s market cap, and Datadog Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and DexCom, Inc. for 62 Days on average.
| DDOG | DXCM | |
|---|---|---|
Market Cap | $98.31B | $31.86B |
Volume | 2,936,660 | 3,607,070 |
Sector | Technology | Health |
52-Week High | $288.15 | $92.34 |
52-Week Low | $102.62 | $54.84 |
Typical Hold Time | 76 Days | 62 Days |
Enterprise Value | $94.61B | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $271.34, down 2.48% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators are neutral. Fundamentally, revenue growth is robust, rising from $1.7B in 2022 to $3.43B in 2025, though net income margins are volatile. Recent earnings beats and accelerating enterprise customer adoption, particularly in AI and cloud observability, support positive sentiment.
The outlook is favorable given analyst consensus and AI-driven demand, but high valuation multiples (P/E 542.68) and negative net cash flow pose risks. Upside potential exists if the company sustains earnings momentum and expands profitability. Key risks include competitive pressures and execution challenges in a high-growth environment.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
